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Abstract
Background: Data on the characteristics of Medication Overuse Headache (MOH) in Latin American (LA) are scarce.
Here we report the demographic and clinical features of the MOH patients from Argentina and Chile enrolled in
the multinational COMOESTAS project in the period 2008–2010.
Methods: The LA population was formed by 240 MOH subjects, 110 from Chile and 130 from Argentina, consecutively
attending the local headache centres. In each centre, specifically trained neurologist interviewed and confirmed the
diagnosis according to the ICHD-II criteria. A detailed history was collected on an electronic patient record form.
Results: The mean patient age was 38.6 years, with a female/male ratio of 8:2. The mean time since onset of the
primary headache was 21 years, whereas duration of MOH was 3.9 years. The primary headache was migraine without
aura in 77.5 % and migraine with aura in 18.8 %. Forty two % of the patients self-reported emotional stress associated
with the chronification of headache; 43.8 % reported insomnia. The most overused medications were acute drug
combinations containing ergotamine (70 %), NSAIDs (33.8 %) and triptans (5.4 %).
Conclusion: Though little described, MOH is present also in LA, where it affects mostly women, in the most active
decades of life. Some differences emerge as regards the demographic and clinical characteristics of MOH in this
population as compared to Europe or Northern America. What seems more worrying about MOH in Argentina and
Chile is that most patients overuse ergotamine, a drug that may cause serious adverse events when used chronically.
These findings once more underscore the importance of properly diagnose and treat MOH.
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Background
Medication overuse headache (MOH) is defined by the
chronification of an episodic headache in association with
the excessive use of any type of symptomatic medication. It
has been recognized for over 50 years [1]. It primarily
affects women (3.5:1), with an average age of 40 and is usu-
ally diagnosed several years after overuse has started [2, 3].
In the vast majority of patients, it is possible to recognize a
previous primary headache, in most cases represented by
migraine [4, 5]. Triptans and non steroid anti-inflammatory
drugs (NSAIDs) are the main prescription drugs overused
in Western Europe [6, 7]. Some risk factors have been pro-
posed for MOH: high frequency of both pain medication
use and pain episodes, use of two or more different medica-
tions, coexistence of other body pains, high levels of daily
stress, low socio-economic status, psychiatric comorbidities
[1, 8, 9]. European epidemiological studies have shown a
prevalence of 1 to 3 % [10–12], but in specialized headache
centres the percentage markedly increases [13, 14]. Precise
epidemiological data about the prevalence of MOH in Latin* Correspondence: rfadic@med.puc.cl
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Americaare lacking. In Chile, for instance, though the con-
dition has been known for many years [15], there is only
one publication investigating the epidemiology of chronic
headache, but not focused on MOH [16]. In this paper we
present the main demographic and clinical characteristics
of MOH in a population of 240 MOH sufferers living in
Argentina and Chile.
Methods
We evaluated 240 patients consecutively visited in the
Neurology Department of Pontificia Universidad Católica
de Chile (PUC) and in the Integral Pain Center at the Fun-
dación para la Lucha contra las Enfermedades Neurológi-
cas Infantiles (FLENI), Argentina, from January 2008 to
December 2010 by neurologists who underwent the
specific training for MOH diagnosis developed within the
COMOESTAS project [17, 18]. Both LA institutions take
care of privately insured patients. Most of the patients in-
cluded in the protocol were recruited during spontaneous
headache consultation at the outpatient clinics both cen-
ters (98.3 %). Very few patients were recruited while hos-
pitalized. As patients were enrolled before the publication
of ICDH-IIIbeta [19], the diagnosis of primary headaches
(migraine, chronic migraine and tension-type headache)
and MOH was made on ICHDII [20] and ICHDII-R
criteria [21]. For the scopes of the present paper, diagnoses
were then reviewed and confirmed retrospectively using
the ICHDIII beta criteria.
Demographic data, habits, personal and family medical
history were recorded, as well as MOH history, MOH
characteristics and medications being overused. All the
information included in this paper was obtained through
a thorough anamnestic report.
The data were collected within the activities of the
COMOESTAS project, which obtained the approval of
the Research Ethics Committee at the Medical School of
Pontificia Universidad Católica de Chile and the Ethics
Committee and Biomedical Research at FLENI. Written
consent was obtained for all patients.
Statistical analysis
The categorical variables were described as absolute and
relative frequency. The continuous variables were described
as mean and standard deviation. The level of significance
was set to p < 0.05.
All of the analyses were done with the Program: SPSS
Inc. Released 2008. SPSS Statistics for Windows, Version
17.0. Chicago: SPSS Inc.
Results
Of the 240 patients evaluated, 110 were enrolled in Chile
and 130 in Argentina. The mean age was 38.7 years
(range: 18–72), 80.4 % of patients were women, 75 % had
a technical or university educational level. The main char-
acteristics of the study population are given in Table 1.
Headache characteristics
Migraine without aura was the most common primary
headache (77.8 %) prior to MOH. In decreasing order,
we found migraine with aura (18.8 %), chronic tension-
type headache (15.9 %), and episodic tension-type head-
ache (8.4 %). A minority of patients had chronic
migraine as their primary headache. In a minority of
patients two types of primary headaches coexisted. Some
patients did have more than one headache type. The
average age of onset of the primary headache was
17.7 years. Noteworthy, in 52.3 % of subjects, headache
started below the age of 16. Headache chronification
was related to self-reported stress in 42.7 % of patients.
Related conditions and habits
Mood and anxiety disorder were common in our patients
past medical history: depression was reported in 26.3 %,
anxiety in 20.8 %, and insomnia in 43.8 %. Hypertension
was present in 12.9 %. Family history was positive for
depression in 32.5 %, for alcoholism in 17.5 % and for any
type of headache in 73.3 %. Habits findings were notable as
regards the use of phosphodiesterase inhibitors beverages
on a daily basis: coffee 51.7 %, tea 51.7 %, cola beverages
33.3 % and mate 27.1 %, in most cases in association.
44.2 % of patients drank a moderate amount of alcohol (less
than 0.5 L of wine per day) and 26.3 % smoked cigarettes.
Medications overused
Average length of overuse was 3.9 years (range 1–30
years). In this population, the majority of subjects over-
used ergotamines (70 %, alone or combined with NSAIDs
or caffeine), 33.9 % overused exclusively NSAIDs, 6.3 %
combination drugs, and only 5.4 % triptans alone (more
than one type of triptans in some cases). The clinical
characteristics of patients are given in Table 2.
Use of medical resources
In the year prior to the evaluation, 30.1 % of our patients
sought help at the emergency room at least once due to
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headache, with a range of 1 to 20 visits. 26.8 % consulted
a general physician and 37.7 % went for a neurological
evaluation at least once. 27.5 % of participants had a
head computerized tomography in the last year.
Discussion
The Latin American section of the COMOESTAS Pro-
ject represents the largest group of MOH patients pub-
lished from this region. The demographic profile that
has emerged is similar to the published data from devel-
oped countries [22], though it is worth noting that both
participating medical centers treat patients with private
health insurance, which explains the high educational
level of the group studied. Our results might therefore
not be representative of the general population in our
countries. It is necessary to note that Argentina and
Chile are the countries with the highest level of educa-
tion and income in the region; therefore caution must
be used when attempting to extrapolate these results to
other Latin America countries with certainly.
In agreement with other reports on MOH in other parts
of the world, also in this series migraine is by far the most
frequently reported primary headache [15, 16, 23]. The
average medication overuse time in this series is signifi-
cantly shorter than previously described [3–5], even
though the time passed since the onset of the primary
headache is similar. This finding may be related to the
exclusion criteria of the COMOESTAS Project, which
required naïf MOH subjects (patients without a history of
previous failure in detoxification therapy).
In the present series, ergotamine is the drug most fre-
quently overused. This is likely due to the fact that med-
ications containing ergotamine are both the cheapest
and most readily available headache treatments in Chile
and Argentina, where they are sold without prescription.
Similar to the Katsarava’s studies [8, 9] a relevant per-
centage of patients in this series made a relation between
chronification of pain and stressful situations. At vari-
ance, the percentage of subjects with diagnosis of depres-
sion or anxiety in our population seems lower than
reported in other countries [24]. Even though this could be
related to the different methods used for diagnosing depres-
sion in the different studies (here we adopted Hospital
Anxiety and Depression Scale, HADS), the lower frequency
of depression could be linked to the shorter duration of
overuse in our series. This raises the possibility that depres-
sion and anxiety in MOH may be a consequence of chronic
pain, rather than a risk factor.
The tendency to consult a neurologist instead of a pri-
mary physician for headaches is characteristic of our
study population. Most of our patients are privately
insured and tend to choose for themselves who will pro-
vide their care. This is a feature of our mixed health
insurance system with some patients being served by a
public system, while other have access to a private one.
Conclusion
In conclusion, though little described, MOH is present also
in LA, where it affects mostly women, in the most active
decades of life. Some differences emerge as regards the
demographic and clinical characteristics of MOH in this
LA population when compared to Europe or Northern
America. What seems more worrying about MOH in
Argentina and Chile is that most patients overuse ergota-
mine, a drug that has been banned from many European
countries because of the high risk of toxicity associated to
its chronic use. These findings once more underscore the
importance of properly diagnose and treat MOH.
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Table 2 Clinical characteristics of the population
Medium Sd
Age at onset 17.7 8.5
(years)
Days of drug intakes/month 21.5 6.9
Headaches days/month 22.4 6.1
Duration of overuse (years) 3.9 4.4
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